Atogepant for the Preventive Treatment of Episodic Migraine
Listen now
Description
Atogepant is FDA approved for the prevention of episodic migraine, and is under review for the prevention of chronic migraine at the time of publication. Stay tuned as Dr. Cynthia E. Armand discusses the goals of migraine prevention, atogepant clinical trial data, how it compares to other gepant medications, side effects, and more.   *The contents of this podcast are intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. AMD and the speaker do not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.
More Episodes
In this episode, leading researcher Dr. Messoud Ashina explains what PACAP is and how it is involved in migraine pathophysiology. He also talks about how it differs from CGRP and why it could be a promising target for migraine and other headache disorders.   Read the transcript at ...
Published 05/06/24
Published 05/06/24
In this episode, dive deeper into the world of migraine disease as we explore Hemiplegic Migraine and Migraine with Unilateral Motor Symptoms (MUMS). Dr. Thomas Berk unpacks the intricacies of these diseases and their differences, while Cannon Hodge shares her personal journey living with MUMS. ...
Published 04/01/24